Close Menu

NEW YORK — Exagen reported after the close of the market on Tuesday a 24 percent year-over-year increase in fourth quarter revenues as a result of record orders of its flagship Avise tests.

For the three month period ended Dec. 31, 2020, Exagen's revenues rose to $12.7 million from $10.2 million in the same period a year earlier. It beat the consensus Wall Street estimate of $10.8 million in revenues for the recently completed quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.